BMI 23, not 30
South Asians develop Type 2 diabetes at body weight levels considered healthy by Western standards. Our risk appears 5–10 years earlier.
The Science
1.8 billion people. Less than 2% of the data.
Indian biology, finally on the map.
Most genetic tests measure you against a biology that isn’t yours. WinDNA is built differently — every marker, every risk score, every recommendation is calibrated for South Asian genetics. Real precision starts with the right reference.
When the reference is wrong, everything is wrong.
South Asian biology is genuinely different — and clinically significant. Here’s what changes when you measure us against ourselves, not someone else’s data.
2–4× higher
South Asians experience cardiovascular events at the same cholesterol levels at significantly higher rates than Western populations — driven by genetic and metabolic differences.
Different metabolism
Variants in CYP2C19 and CYP2D6 — the genes that process common medications — appear at different frequencies in South Asians. Standard dosing isn’t always standard for us.
Built on South Asian reference data. Reviewed by Indian clinicians.
Calibration isn’t a single step — it’s the entire process. Sample to report, every layer is tuned for the population it serves.
-
01
Population Reference
Polygenic risk scores recalibrated against South Asian cohorts — including ICMR-INDIAB, GenomeAsia 100K, and our own research collaborations. Western database values are adjusted or replaced where the biology demands it.
-
02
Lab Sequencing
NABL-accredited laboratories operating under ISO 15189 quality systems. Every sample undergoes orthogonal validation before clinical interpretation begins.
-
03
Variant Interpretation
ACMG classification standards combined with population-adjusted frequency data. Every variant of clinical significance is reviewed by a certified clinical geneticist — not algorithmic-only interpretation.
-
04
Clinical Sign-Off
An Indian clinician reviews the full report, contextualises findings against South Asian biology, and signs off on every recommendation before delivery. No black-box reports.
Built on peer-reviewed science. Tested in real clinical settings.
200+
clinically validated genetic markers across preventive, hereditary, and pharmacogenomic panels
85%
of disease-causing variants captured by Whole Exome Sequencing — the foundation of our clinical panels
30+
FDA and CPIC-recognised drug-gene pairs covered in our pharmacogenomic interpretation
Selected Foundations
- GenomeAsia 100K — Nature, 2019
- ICMR-INDIAB Study — Lancet Diabetes & Endocrinology, 2023
- South Asian polygenic risk calibration — Nature Communications, 2024
- ACMG Standards & Guidelines — Genetics in Medicine, 2023
Every protocol. Every certification.
Lab Standards
- NABL Accredited (National Accreditation Board for Testing and Calibration Laboratories)
- ISO 15189 Quality Management
- Sample chain of custody documented end-to-end
- CAP-equivalent protocols for hereditary and pharmacogenomic panels
- Orthogonal validation on all clinically significant findings
Data & Privacy
- DPDP Act 2023 compliant infrastructure
- All patient data India-resident
- Encryption at rest and in transit
- Right to deletion guaranteed
- No third-party data sharing — ever
Active research partnerships across India’s leading institutions.
Calibrated science requires ongoing research. WinDNA collaborates with academic and clinical institutions across India to expand reference data, validate findings, and refine interpretation.
Sambalpur University
Research collaboration in natural-herb pharmacogenomics — mapping how Indian medicinal plants interact with genetic drug-metabolism variants.
AIC-RMP Mumbai
Atal Incubation Centre — clinical validation studies, healthcare innovation programmes, and entrepreneurship support.
NABL Lab Network
India-wide accredited laboratory partnerships ensuring sample handling standards across every region we serve.
Real precision starts with the right reference.
Talk to our team about which panel matches your goals, your biology, and your timing.